Science and Research

Pulmonary hypertension associated with lung disease: new insights into pathomechanisms, diagnosis, and management

Patients with chronic lung diseases, particularly interstitial lung disease and chronic obstructive pulmonary disease, frequently develop pulmonary hypertension, which results in clinical deterioration, worsening of oxygen uptake, and an increased mortality risk. Pulmonary hypertension can develop and progress independently from the underlying lung disease. The pulmonary vasculopathy is distinct from that of other forms of pulmonary hypertension, with vascular ablation due to loss of small pulmonary vessels being a key feature. Long-term tobacco exposure might contribute to this type of pulmonary vascular remodelling. The distinct pathomechanisms together with the underlying lung disease might explain why treatment options for this condition remain scarce. Most drugs approved for pulmonary arterial hypertension have shown no or sometimes harmful effects in pulmonary hypertension associated with lung disease. An exception is inhaled treprostinil, which improves exercise capacity in patients with interstitial lung disease and pulmonary hypertension. There is a pressing need for safe, effective treatment options and for reliable, non-invasive diagnostic tools to detect and characterise pulmonary hypertension in patients with chronic lung disease.

  • Olsson, K. M.
  • Corte, T. J.
  • Kamp, J. C.
  • Montani, D.
  • Nathan, S. D.
  • Neubert, L.
  • Price, L. C.
  • Kiely, D. G.

Keywords

  • Humans
  • *Hypertension, Pulmonary/diagnosis/etiology/therapy
  • *Pulmonary Disease, Chronic Obstructive
  • *Pulmonary Arterial Hypertension
  • Familial Primary Pulmonary Hypertension
  • *Clinical Deterioration
Publication details
DOI: 10.1016/s2213-2600(23)00259-x
Journal: Lancet Respir Med
Pages: 820-835 
Number: 9
Work Type: Review
Location: BREATH
Disease Area: PH
Partner / Member: MHH
Access-Number: 37591300

DZL Engagements

chevron-down